Last reviewed · How we verify
NCT07275840
A Study to Evaluate the Efficacy and Safety of IBI302inSubjects With nAMD
Phase 2 trial testing IBI302 8mg dose in Neovascular Age-related Macular Degeneration in 800 participants. Currently enrolling.
30 August 2026
Quick facts
| Lead sponsor | Innovent Biologics Technology Limited (Shanghai R&D Center) |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 800 |
| Start date | 5 December 2025 |
| Primary completion | 30 August 2026 |
| Estimated completion | 30 August 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- IBI302 8mg dose — full drug profile →
Conditions studied
- Neovascular Age-related Macular Degeneration — all drugs for Neovascular Age-related Macular Degeneration →
Sponsor
Innovent Biologics Technology Limited (Shanghai R&D Center) — full company profile →
Who can join
50 and older, any sex, with Neovascular Age-related Macular Degeneration. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is designed for Open-label, multi-center, single-arm Phase II trail to evaluate the efficacy and safety of intravitreal injection of IBI302 in nAMD patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07275840
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Neovascular Age-related Macular Degeneration
Currently open trials in the same condition.
- NCT06847542 — A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD · Phase 3 · recruiting
- NCT07053358 — Safety and Efficacy Evaluation of LX111 Gene Therapy in nAMD Patients · EARLY_PHASE1 · recruiting
- NCT06680817 — A Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study) · recruiting
- NCT06495918 — Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- R · Phase 3 · active not recruiting
- NCT06660667 — A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration · Phase 1, PHASE2 · recruiting
Other Innovent Biologics Technology Limited (Shanghai R&D Center) trials
Trials by the same sponsor.
- NCT07414394 — Tigulixostat (IBI128) vs Febuxostat in Gout · Phase 3 · recruiting
- NCT07327632 — This is a Multi-Center Study of IBI3026 in Participants With Locally Advanced, Unresectable or Metastatic Solid Tumors · EARLY_PHASE1 · recruiting
- NCT07170319 — A Study of IBI3032 in Chinese Participants With Overweight or Obesity · Phase 1 · active not recruiting
- NCT07160400 — A Study of IBI3032 in Chinese Healthy Participants and Participants With Overweight or Obesity · Phase 1 · recruiting
- NCT07134127 — A Study of IBI3032 in Chinese Healthy Subjects · EARLY_PHASE1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07275840 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Innovent Biologics Technology Limited (Shanghai R&D Center)
- Last refreshed: 8 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07275840.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing